Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Whose Burden Is It Anyway? REMS’ Health Care Impact Belongs To FDA, PhRMA Says

Executive Summary

Industry group contends that FDA should assess whether a REMS places an undue burden on the health care industry – because asking companies to do that evaluation would be an additional burden on the health care system.


Related Content

Postmarket Data Tops FDA’s Research Wish List In Safety Self-Assessment
REMS Communications Need FDA Logo To Boost Doctors’ Attention, Advisors Say
REMS Communications Could Get Refreshed After Advisory Panel Meeting
REMS Modification Studies Could Use Foreign Markets As Controls
REMS Assessment Paradigm To Be RE-AIMed By FDA; “Pressure-Testing” Needed
REMS Strength Driven More By Drug’s Benefits Than Risks, FDA Suggests
REMS Need Metrics For Assessing Success, Burden On Health Care System
FDA's Chicken Or Egg Question For Pharmacy Leaflets: Should Benefit Or Risk Come First?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts